NCT04887025 is a Phase 1 clinical trial of RGV004 in Relapsed or Refractory B-cell Lymphoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04887025?

NCT04887025 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04887025?

Interventions in NCT04887025: RGV004.

What condition does NCT04887025 study?

NCT04887025 studies Relapsed or Refractory B-cell Lymphoma.

Is NCT04887025 still recruiting?

NCT04887025 is currently status unknown. Last updated 6 February 2023.

Last reviewed 2023-02-06 · How we verify

NCT04887025

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

Status unknown Phase 1 Last updated 6 February 2023

What this trial tests

Phase 1 trial testing RGV004 in Relapsed or Refractory B-cell Lymphoma in 25 participants. Status unknown.

Timeline

8 February 2022

Primary endpoint
15 March 2023

15 March 2025

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	8 February 2022
Primary completion	15 March 2023
Estimated completion	15 March 2025
Sites	1 location across China

Drugs / interventions tested

RGV004 — full drug profile →

Conditions studied

Relapsed or Refractory B-cell Lymphoma — all drugs for Relapsed or Refractory B-cell Lymphoma →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 75, any sex, with Relapsed or Refractory B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a dose-escalation, single-arm, single-center open study which aims to evaluate the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of a novel oncolytic vaccinia virus expressing bispecific antibody RGV004 in patients with relapsed/refractory B-cell lymphoma,

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
Tian Y, Xie D, Yang L. · · 2022 · cited 199× · PMID 35387984 · DOI 10.1038/s41392-022-00951-x
Biomaterial-Based In Situ Cancer Vaccines.
Bo Y, Wang H. · · 2024 · cited 55× · PMID 36649567 · DOI 10.1002/adma.202210452
Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective.
Muthukutty P, Yoo SY. · · 2023 · cited 45× · PMID 37631987 · DOI 10.3390/v15081645
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO, Hong J, Yoon AR. · · 2022 · cited 45× · PMID 36091031 · DOI 10.3389/fimmu.2022.953410
Oncolytic vaccinia virus and cancer immunotherapy.
Xu L, Sun H, Lemoine NR, Xuan Y, et al · · 2023 · cited 36× · PMID 38283361 · DOI 10.3389/fimmu.2023.1324744
Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
Fang C, Xiao G, Wang T, Song L, et al · · 2023 · cited 36× · PMID 37040283 · DOI 10.34133/research.0108
Recent progress in combination therapy of oncolytic vaccinia virus.
Mirbahari SN, Da Silva M, Zúñiga AIM, Kooshki Zamani N, et al · · 2024 · cited 25× · PMID 38558795 · DOI 10.3389/fimmu.2024.1272351
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M, Kadkhodazadeh M, Shapourabadi MB, Goradel NH, et al · · 2022 · cited 25× · PMID 36311790 · DOI 10.3389/fimmu.2022.1012806

Verify or expand the search:

Other recruiting trials for Relapsed or Refractory B-cell Lymphoma

Currently open trials in the same condition.

NCT05806580 — Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma · Phase 4 · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04887025 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 6 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04887025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing